These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30922481)

  • 1. Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists.
    Vaduganathan M; Patel RB; Singh A; McCarthy CP; Qamar A; Januzzi JL; Scirica BM; Butler J; Cannon CP; Bhatt DL
    J Am Coll Cardiol; 2019 Apr; 73(12):1596-1598. PubMed ID: 30922481
    [No Abstract]   [Full Text] [Related]  

  • 2. Changes in the Prescription of Glucose-Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study.
    Fadini GP; Frison V; Simioni N; Lapolla A; Gatti A; Bossi AC; Del Buono A; Fornengo P; Gottardo L; Laudato M; Perseghin G; Bonora E; Avogaro A
    J Am Heart Assoc; 2019 Jul; 8(14):e012244. PubMed ID: 31269877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihyperglycemic Therapies With Expansions of US Food and Drug Administration Indications to Reduce Cardiovascular Events: Prescribing Patterns Within an Academic Medical Center.
    Hamid A; Vaduganathan M; Oshunbade AA; Ayyalasomayajula KK; Kalogeropoulos AP; Lien LF; Shafi T; Hall ME; Butler J
    J Cardiovasc Pharmacol; 2020 Sep; 76(3):313-320. PubMed ID: 32569016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Which person with diabetes should receive cardioprotective glucose-lowering medicines?
    Bloomgarden ZT
    J Diabetes; 2020 May; 12(5):352-353. PubMed ID: 32119186
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiologists' approach to managing cardiovascular risk in patients with type 2 diabetes.
    Rocha N; Das SR
    J Diabetes; 2019 Jul; 11(7):605-609. PubMed ID: 31044534
    [No Abstract]   [Full Text] [Related]  

  • 6. Glucagon-Like Peptide-1 Receptor Agonists and Prevention of Stroke Systematic Review of Cardiovascular Outcome Trials With Meta-Analysis.
    Bellastella G; Maiorino MI; Longo M; Scappaticcio L; Chiodini P; Esposito K; Giugliano D
    Stroke; 2020 Feb; 51(2):666-669. PubMed ID: 31813360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide.
    Alatorre C; Fernández Landó L; Yu M; Brown K; Montejano L; Juneau P; Mody R; Swindle R
    Diabetes Obes Metab; 2017 Jul; 19(7):953-961. PubMed ID: 28181725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updated Meta-Analysis of Cardiovascular Outcome Trials Evaluating Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor Agonists.
    Patoulias D; Papadopoulos C; Kassimis G; Karagiannis A; Doumas M
    Am J Cardiol; 2021 Nov; 159():143-146. PubMed ID: 34497008
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.
    Med Lett Drugs Ther; 2019 Feb; 61(1566):26-28. PubMed ID: 30845101
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical Efficacy and Mechanisms of Actions of the Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and High Risk of Cardiovascular Diseases].
    Gilarevsky SR
    Kardiologiia; 2021 May; 61(4):66-72. PubMed ID: 33998411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - A systematic review and meta-analysis.
    Goldenberg RM
    J Diabetes Complications; 2022 Sep; 36(9):108285. PubMed ID: 35998555
    [No Abstract]   [Full Text] [Related]  

  • 12. Glucagon-like peptide-1 receptor agonists as anti-inflammatory agents: A potential mode of cardiovascular benefits.
    Salem AM; Bain SC; Obaid DR
    Atherosclerosis; 2022 Jul; 352():83-84. PubMed ID: 35662526
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review.
    Honigberg MC; Chang LS; McGuire DK; Plutzky J; Aroda VR; Vaduganathan M
    JAMA Cardiol; 2020 Oct; 5(10):1182-1190. PubMed ID: 32584928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013-2018.
    Dave CV; Schneeweiss S; Wexler DJ; Brill G; Patorno E
    Diabetes Care; 2020 Apr; 43(4):921-924. PubMed ID: 32041899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns.
    Lim S; Kim KM; Nauck MA
    Trends Endocrinol Metab; 2018 Apr; 29(4):238-248. PubMed ID: 29463450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrate use in the United States and Canada.
    Lim LS; Wong TY
    JAMA; 2011 Jul; 306(2):157-8; author reply 158-9. PubMed ID: 21750289
    [No Abstract]   [Full Text] [Related]  

  • 17. GLP-1 receptor agonists and cardiovascular outcome trials: An update.
    Andrikou E; Tsioufis C; Andrikou I; Leontsinis I; Tousoulis D; Papanas N
    Hellenic J Cardiol; 2019; 60(6):347-351. PubMed ID: 30528435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics and glucose-lowering drug utilization among patients initiating liraglutide in Denmark: a routine clinical care prescription study.
    Knudsen JS; Thomsen RW; Pottegård A; Knop FK; Sørensen HT
    J Diabetes; 2019 Aug; 11(8):690-694. PubMed ID: 30893522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No pancreatic safety concern following glucagon-like peptide-1 receptor agonist therapies: A pooled analysis of cardiovascular outcome trials.
    Liu Y; Tian Q; Yang J; Wang H; Hong T
    Diabetes Metab Res Rev; 2018 Nov; 34(8):e3061. PubMed ID: 30109766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of glucagon-like peptide-1 receptor agonists on kidney function and safety in type 2 diabetes patients.
    Kim MK; Kim DM
    J Diabetes Investig; 2021 Jun; 12(6):914-916. PubMed ID: 33759351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.